Notice of Full Year Results
13 October 2022
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
NOTICE OF FULL YEAR RESULTS
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, will announce its full year results for the year ended 30 June 2022 on Tuesday 18 October 2022.
Aptamer Group's CEO, Arron Tolley, Interim CFO, Jenny Cutler and CTO, David Bunka, will be hosting an in-person meeting and webcast for sell-side analysts at 10.00am BST on 18 October 2022. To register your interest in attending, please email [email protected].
- ENDS -
For further information, please contact:
Aptamer Group plc
Dr Arron Tolley +44 (0) 1904 56 7790
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott / Adam Dawes +44 (0) 20 3368 3550
Liberum Capital Limited - Broker
Richard Lindley / Ben Cryer / Will Hall / Cara Murphy +44 (0) 20 3100 2000
Consilium Strategic Communications
Matthew Neal / Chris Welsh / Lucy Featherstone +44 (0) 20 3709 5700
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.